Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

AZNATRON

I'm Interested!

A Multicentre, Randomised, Doubleblind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

  • Sex at Birth: Any
  • Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase III
  • Conditions Being Studied: Hypereosinophilic Syndrome

Study Purpose

HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction. Benralizumab is an antibody (i.e. biologic drug) that has been made to reduce the number of eosinophils in the body. A previous benralizumab HES study showed that benralizumab may reduce eosinophils in blood and tissues in patients with severe HES that is not well controlled by standard of care medications. The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to available standard of care HES medications which you are currently taking

Principal Investigator
Princess Ogbogu MD
Department/Division
Allergy Immunology (Pediatrics)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: SITE00001311
  • StudyID: 2021-0516
  • ClinicalTrials.gov: NCT04191304
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422